206879-72-3

Basic information

• Product Name: 4-(3-AMINO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 1-(3-AMINO-PHENYL)-PIPERAZINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER;4-(3-AMINO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;3-(4-Boc-piperazin-1-yl)aniline;tert-butyl 4-(3-aMinophenyl)piperazine-1-carboxylate;1-Boc-4-(3-aminophenyl)piperazine;1-Piperazinecarboxylic acid, 4-(3-aMinophenyl)-, 1,1-diMethylethyl ester;4-(3-Aminophenyl)-1-piperazinecarboxylic acid 1,1-dimethylethyl ester
• CAS NO: 206879-72-3
• Molecular Formula: C₁₅H₂₃N₃O₂
• Molecular Weight: 277.36
• Product Categories: pharmacetical
• Mol File: 206879-72-3.mol

Chemical Properties

• Boiling Point: 442.427°C at 760 mmHg
• Flash Point: 221.372°C
• Appearance: /
• Density: 1.145
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.567
• PKA: 5.35±0.10(Predicted)
• CAS DataBase Reference: 4-(3-AMINO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-AMINO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(206879-72-3)
• EPA Substance Registry System: 4-(3-AMINO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(206879-72-3)

Safety Data

• Hazardous Substances Data: 206879-72-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-AMINO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a synthetic intermediate for the preparation of 5-amino-1-heterocyclyl-1H-pyrazole derivatives. These derivatives have demonstrated anti-tumor properties, making them valuable in the development of new anti-cancer drugs.
In the synthesis of these anti-tumor agents, tert-Butyl 4-(3-Aminophenyl)-1-piperazinecarboxylate plays a crucial role in the formation of the heterocyclic pyrazole ring system, which is often associated with biological activity. The compound's reactivity and functional groups allow for further chemical modifications, enabling the development of a diverse range of potential therapeutic agents targeting various types of cancer.

InChI:InChI=1/C15H23N3O2/c1-15(2,3)20-14(19)18-9-7-17(8-10-18)13-6-4-5-12(16)11-13/h4-6,11H,7-10,16H2,1-3H3

Upstream product

• 585-79-5 m-nitrobromobenzene 
• 54054-85-2 1-(3-nitrophenyl)piperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 206879-94-9 4-(3-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 900800-89-7 1-[3-methylsulfonylaminophenyl]-4-tert-butoxycarbonyl-piperazine 
• 1374213-82-7 4-(1-phenylcyclopropylamino)-6-(3-(piperazin-1-yl)phenylamino)nicotinamide 
• 1374213-83-8 6-(3-(4-acetylpiperazin-1-yl)phenylamino)-4-(1-phenylcyclopropylamino)nicotinamide 
• 1374215-26-5 C₃₀H₃₆N₆O₃ 
• 1138473-41-2 4-(benzo[b]thiophen-2-yl)-5-methyl-N-(3-(piperazin-1-yl)phenyl)pyrimidin-2-amine 
• 1235588-42-7 8-indan-5-yl-5-oxo-2-[3-(4-boc-piperazin-1-yl)-phenylamino]-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 936092-62-5 4-{3-[4-(4-chloro-3-methoxy-phenylamino)-5-methyl-pyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic acid tert butyl ester 

Relevant articles and documents

DRUG CONJUGATES AND USES THEREOF

The invention generally relates to the design and production of drug conjugates, and specifically conjugates of antibiotic agents to cationic and non-cationic molecular transporters.

Synthesis and structure-activity relationships of new 2-phenoxybenzamides with antiplasmodial activity

The 2-phenoxybenzamide 1 from the Medicines for Malaria Venture Malaria Box Project has shown promising multi-stage activity against different strains of P. falciparum. It was successfully synthesized via a retrosynthetic approach. Subsequently, twenty-one new derivatives were prepared and tested for their in vitro activity against blood stages of the NF54 strain of P. falciparum. Several insights into structure-activity relationships were revealed. The antiplasmodial activity and cytotoxicity of compounds strongly depended on the substitution pattern of the anilino partial structure as well as on the size of substituents. The diaryl ether partial structure had further impacts on the activity. Additionally, several physicochemical and pharmacokinetic parameters were calculated (log P, log D7.4 and ligand efficiency) or determined experimentally (passive permeability and CYP3A4 inhibition). The tert-butyl-4-{4-[2-(4-fluorophenoxy)-3-(trifluoromethyl)benzamido]phenyl}piperazine-1-carboxylate possesses high antiplasmodial activity against P. falciparum NF54 (PfNF54 IC50 = 0.2690 μM) and very low cytotoxicity (L-6 cells IC50 = 124.0 μM) resulting in an excellent selectivity index of 460. Compared to the lead structure 1 the antiplasmodial activity was improved as well as the physicochemical and some pharmacokinetic parameters.

NOTCH INHIBITORS AND USES THEREOF

Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.

Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists

Loss of orexin-producing neurons results in narcolepsy with cataplexy, and orexin agonists have been shown to increase wakefulness and alleviate narcolepsy symptoms in animal models. Several OX2R agonists have been reported but with little or no activity

PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS

Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2) and/or receptor interacting kinase 3 (RIPK3). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 or RIPK3 could provide therapeutic benefit. Compounds that function as RIPK3 inhibitors provide therapeutic benefit in the treatment of inflammatory and degenerative conditions.

PYRIDO[2,3-D]PYRIMIDIN-7ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds having the structures below (I) are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.

NICOTINAMIDES AS JAK KINASE MODULATORS

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.

OXAZOLE TYROSINE KINASE INHIBITORS

The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1 : provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.